A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Public ClinicalTrials.gov record NCT02588625. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT02588625
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- BMS-986020 Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2016
- Primary completion
- Sep 30, 2019
- Completion
- Sep 30, 2019
- Last update posted
- Jul 21, 2016
2016 – 2019
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Scottsdale | Arizona | 85259 | — |
| Local Institution | Los Angeles | California | 90095 | — |
| Local Institution | Stanford | California | 94305 | — |
| Local Institution | Aurora | Colorado | 80045 | — |
| Local Institution | Washington D.C. | District of Columbia | 20037 | — |
| Local Institution | Washington D.C. | District of Columbia | 20057 | — |
| Local Institution | Chicago | Illinois | 60611 | — |
| Local Institution | Baltimore | Maryland | 21205 | — |
| Local Institution | Boston | Massachusetts | 02114 | — |
| Local Institution | Boston | Massachusetts | 02118 | — |
| Local Institution | Ann Arbor | Michigan | 48109 | — |
| Local Institution | New Brunswick | New Jersey | 08903 | — |
| Local Institution | Albany | New York | 12206 | — |
| Local Institution | New York | New York | 10021 | — |
| Local Institution | New York | New York | 10032 | — |
| Local Institution | Cleveland | Ohio | 44195 | — |
| Local Institution | Pittsburgh | Pennsylvania | 15219 | — |
| Local Institution | Charleston | South Carolina | 29425 | — |
| Local Institution | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02588625, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02588625 live on ClinicalTrials.gov.